[{"text": "Arcutis to Present at the Guggenheim SMID Cap Biotech Conference Arcutis Biotherapeutics, Inc. Mon, Jan 27, 2025, 4:00 PM 3 min read In This Article: ARQT -4.15% Arcutis Biotherapeutics, Inc. WESTLAKE VILLAGE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025. Details for the company\u2019s participation are as follows: Fireside Chat Date: Thursday, February 6, 2025 Fireside Chat Time : 1:00 pm ET The webcast for this conference may be accessed at the \u201c Events \u201d section of the Company\u2019s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference. About Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis\u2019 dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit http://www.arcutis.com or follow Arcutis on LinkedIn , Facebook , Instagram , and X . Forward-Looking Statements This press release and the anticipated fireside chat discussion contain \u201cforward-looking\u201d statements, including, among others, statements regarding Arcutis\u2019 potential to address urgent needs and expectations with regard to the timing of data and regulatory events. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the \u201cRisk Factors\u201d section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Story Continues Contacts: Media Amanda Sheldon, Head of Corporate Communications media@arcutis.com Investors Latha Vairavan, Vice President, Finance and Corporate Controller ir@arcutis.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-27T13:00:00+00:00", "sentiment": {"score": 0.22934196796268225, "confidence": 0.23745429515838623, "probabilities": {"positive": 0.23745429515838623, "negative": 0.008112327195703983, "neutral": 0.7544333934783936}}, "embedding": [-0.10914519429206848, -0.12793925404548645, -0.03871782124042511, 0.0806257352232933, 0.10324201732873917, -0.033193521201610565, 0.040766626596450806, 0.12431810796260834, -0.052211225032806396, 0.08841706067323685, -0.11460204422473907, -0.15228918194770813, 0.03209943324327469, 0.16622239351272583, -0.06446456909179688, -0.022728141397237778, 0.0370761901140213, -0.014981366693973541, -0.08040640503168106, 0.03032580204308033, 0.002498212270438671, 0.14002929627895355, -0.001426860224455595, 0.043515145778656006, -0.17514419555664062, -0.09546099603176117, -0.11277762055397034, -0.15228116512298584, -0.31004589796066284, -0.09944424033164978, 0.05856185406446457, 0.030451292172074318, 0.06779729574918747, 0.006624111905694008, 0.0399145632982254, -0.05447022616863251, -0.09237383306026459, 0.07001417875289917, 0.03639176860451698, 0.03270452469587326, -0.1393122375011444, -0.09344182163476944, -0.128655806183815, 0.027769960463047028, 0.1193741112947464, -0.15086673200130463, -0.07009311765432358, 0.01734202727675438, -0.017863092944025993, 0.26748985052108765, -0.08080689609050751, -0.09519782662391663, 0.034826576709747314, 0.042909421026706696, -0.08183504641056061, 0.12915654480457306, -0.12566067278385162, -0.11255970597267151, -0.028662975877523422, -0.06026638299226761, 0.0035383542999625206, -0.19870617985725403, -0.029965022578835487, 0.06402914226055145, 0.05683723837137222, -0.03201336786150932, 0.10989079624414444, 0.05158892646431923, 0.07581407576799393, -0.12173963338136673, 0.005820024758577347, -0.03098127990961075, -0.08420887589454651, 0.2618485987186432, 0.1681056171655655, 0.20416989922523499, 0.10130338370800018, 0.16570276021957397, 0.1676062047481537, 0.00889033917337656, 0.11228347569704056, 0.15802180767059326, 0.12279768288135529, 0.08744633197784424, 0.057416368275880814, 0.05997580662369728, -0.007440514862537384, 0.09419409930706024, -0.06820736825466156, -0.05019151791930199, 0.05066794157028198, 0.0674440786242485, 0.058534346520900726, 0.021762989461421967, 0.04919883608818054, -0.030738849192857742, 0.001738172024488449, 0.06905712932348251, 0.04656045138835907, 0.006075886078178883, -0.15339913964271545, -0.12444233894348145, -0.18849943578243256, -0.08902423083782196, -0.08872857689857483, -0.144217848777771, -0.058050740510225296, -0.06859399378299713, 0.059225402772426605, 0.01325602363795042, 0.03453753888607025, 0.01659218780696392, -0.006275791674852371, -0.1385805308818817, 0.09196944534778595, 0.21440663933753967, 0.0379757359623909, -0.0071450467221438885, 0.18564647436141968, -0.11418268829584122, -0.015073966234922409, 0.02750912681221962, 0.050860170274972916, -0.14162397384643555, -0.04650437831878662, 0.10696938633918762, 0.010781514458358288, 1.089681720375925e-32, -0.04159083962440491, 0.10598601400852203, -0.054917119443416595, 0.04978559911251068, 0.01229500025510788, -0.035122454166412354, 0.059568218886852264, -0.032246820628643036, -0.1322644054889679, -0.040389496833086014, -0.1449357122182846, 0.2398512065410614, 0.053737010806798935, 0.10725521296262741, -0.06882762908935547, -0.056883804500103, 0.048733875155448914, 0.07664164155721664, -0.09758856147527695, -0.13681122660636902, -0.026063429191708565, 0.11384157836437225, -0.061570070683956146, 0.06458175182342529, -0.02841685339808464, 0.17714598774909973, -0.02647145465016365, -0.03798505663871765, 0.12290991097688675, 0.06969130039215088, -0.15775640308856964, 0.10954079031944275, 0.07353197038173676, -0.08661255240440369, 0.007659146562218666, -0.014940474182367325, -0.0947481095790863, -0.19363898038864136, 0.05202995985746384, 0.023657703772187233, -0.07598293572664261, 0.10466128587722778, -0.09122280031442642, -0.06609174609184265, 0.05108744278550148, -0.028800876811146736, -0.0877629965543747, 0.07774985581636429, -0.07287940382957458, 0.04237787425518036, -0.02549084648489952, 0.05705974996089935, 0.10959047079086304, -0.045748189091682434, 0.06513441354036331, 0.032867711037397385, -0.13705579936504364, -0.13979831337928772, 0.1621767282485962, 0.15519842505455017, 0.12874484062194824, 0.04287068918347359, -0.10513685643672943, 0.014415153302252293, -0.16489852964878082, 0.06148742139339447, -0.00490596005693078, 0.018550636246800423, 0.08079776912927628, 0.08395963162183762, 0.017766732722520828, 0.04540155455470085, 0.08710378408432007, 0.05135667324066162, 0.15804266929626465, -0.06686781346797943, 0.0405382476747036, 0.208058163523674, -0.17942285537719727, 0.05694890022277832, -0.07569165527820587, 0.11780168116092682, -0.004922604188323021, 0.11513854563236237, 0.10636062920093536, -0.08566632121801376, -0.013877473771572113, 0.12200440466403961, -0.18166229128837585, -0.037931568920612335, 0.0923500806093216, 0.017279058694839478, -0.0394064299762249, 0.2640759348869324, 0.024693194776773453, -1.00306123143696e-32, 0.05093648284673691, -0.1218128651380539, -0.23130501806735992, -0.09863052517175674, 0.017286645248532295, 0.059372417628765106, 0.06491170823574066, -0.04635556787252426, 0.07402024418115616, 0.0059659965336322784, 0.0577448308467865, -0.00767994299530983, -0.06580983102321625, -0.08244071900844574, -0.08261876553297043, 0.011251002550125122, 0.01932375319302082, -0.1697562336921692, -0.1029585674405098, 0.09672084450721741, 0.02251897193491459, 0.08784527331590652, -0.13363711535930634, -0.0121872304007411, -0.03778918832540512, 0.00471455417573452, 0.10158196091651917, -0.03336881101131439, 0.11767396330833435, -0.060737404972314835, -0.10533265769481659, 0.013284275308251381, -0.2085692286491394, -0.056638266891241074, -0.06436501443386078, 0.01729177124798298, 0.09107938408851624, -0.1909310519695282, -0.03823293000459671, -0.09918913245201111, 0.10043570399284363, -0.08223661780357361, -0.15730398893356323, 0.05754402279853821, 0.15582185983657837, 0.07144682109355927, -0.026344116777181625, 0.04070422798395157, 0.043319009244441986, 0.02734304405748844, 0.04380364343523979, -0.08797506242990494, 0.09863367676734924, -0.027742963284254074, -0.046463049948215485, -0.09482079744338989, 0.000916806049644947, -0.037467215210199356, -0.01498204842209816, 0.06912665069103241, 0.015627339482307434, 0.00652199424803257, -0.007064388133585453, 0.06018509715795517, 0.06543245166540146, 0.06626929342746735, 0.023598946630954742, -0.030073652043938637, -0.08519990742206573, -0.03918074443936348, -0.0005330741405487061, -0.11606758832931519, 0.004616831429302692, -0.14873427152633667, -0.016602616757154465, 0.036762937903404236, -0.05258263647556305, -0.06483961641788483, -0.10129733383655548, 0.12271000444889069, 0.0013900436460971832, -0.03552589565515518, 0.02910693548619747, 0.0929485559463501, 0.12204397469758987, 0.052547652274370193, 0.03786204010248184, -0.00747766625136137, -0.11619589477777481, 0.1367613971233368, -0.09257128089666367, -0.09215588867664337, -0.08651907742023468, 0.1258155107498169, 0.02140912227332592, -1.0050744947420753e-07, 0.2132062315940857, 0.0693393349647522, -0.045223917812108994, -0.09438468515872955, -0.08648136258125305, 0.018264826387166977, -0.12919951975345612, 0.12139022350311279, -0.003665223950520158, 0.08672952651977539, 0.08664014935493469, 0.19114241003990173, -0.0738438293337822, 0.11183730512857437, -0.005895651876926422, 0.05580170452594757, 0.00295151025056839, 0.03973735496401787, -0.07091140747070312, -0.15285147726535797, -0.11925581097602844, 0.036822281777858734, 0.0625789538025856, -0.0548444427549839, 0.039782945066690445, -0.05425088107585907, 0.035575397312641144, 0.04624216631054878, -0.028680693358182907, -0.16067983210086823, -0.08636923879384995, -0.15775611996650696, -0.08198568969964981, -0.02913486585021019, 0.007294937968254089, -0.047720104455947876, -0.06281820684671402, -0.08266110718250275, 0.16471779346466064, 0.10348506271839142, -0.04430737346410751, 0.08479635417461395, 0.007909166626632214, 0.022625161334872246, -0.02559204027056694, -0.05293092876672745, -0.13426434993743896, -0.10039319097995758, 0.01214810460805893, -0.07979489862918854, -0.14497911930084229, -0.16997599601745605, 0.04005748778581619, -0.0010351408272981644, -0.04695972055196762, 0.1429751217365265, 0.1031845435500145, -0.1905464231967926, 0.0890791192650795, 0.06965107470750809, 0.09647317230701447, -0.08199150860309601, 0.09793242067098618, 0.18905594944953918], "changes": {"1wk": -7.087720904433937}}, {"text": "IDXX Gears Up for Q4 Earnings: What to Expect From the Stock? Zacks Equity Research Mon, Jan 27, 2025, 5:07 PM 5 min read In This Article: IDXX +11.13% IDEXX Laboratories, Inc. IDXX is set to release fourth-quarter 2024 results on Feb. 3, before the opening bell. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.80, which surpassed the Zacks Consensus Estimate by 4.1%. IDEXX Laboratories\u2019 earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 0.85%. IDXX\u2019s Q4 Estimates The Zacks Consensus Estimate for revenues is pegged at $936.8 million, indicating an increase of 3.9% from the year-ago figure. The Zacks Consensus Estimate for EPS is pegged at $2.40, indicating an increase of 3.4% from the year-ago figure. Estimate Revision Trend Ahead of IDXX\u2019s Earnings Estimates for fourth-quarter earnings have remained unchanged at $2.40 in the past 30 days. Let\u2019s explore how things might have progressed for the pet healthcare innovator ahead of the announcement. Factors Shaping IDXX\u2019s Q4 Performance Companion Animal Group (\u201cCAG\u201d) In the fourth quarter of 2024, CAG Diagnostics\u2019 recurring revenues are likely to have been supported by improvements in average global net prices and international organic gains. IDEXX Laboratories\u2019 strong execution of strategies might have been a key factor in international growth, reflected in its strong new business gains and more premium instrument placements, boosting the global premium instrument installed base expansion. The U.S. CAG Diagnostic\u2019s recurring revenues are likely to have benefited from new business gains, sustained high customer retention levels and net price realization. Diagnostic utilization per clinical visit must have continued to expand at the clinic level, resulting in higher diagnostic revenue dollars per clinical visit, including diagnostics. We expect the company to have effectively navigated the headwinds from broader cumulative macroeconomic factors affecting consumers and ultimately achieved solid organic CAG Diagnostic revenue growth in the to-be-reported quarter. IDEXX VetLab consumables are expected to have delivered strong organic growth, fueled by robust performance in the United States and international regions. IDEXX Laboratories had earlier planned to launch the inVue Dx Cellular Analyzer in the fourth quarter. Its expanding test menu for the Catalyst platform, including the new Pancreatic Lipase Test, is expected to have strongly favored the segment\u2019s revenues. Within the point-of-care business, IDEXX Catalyst SmartQC was recently launched in North America. Further, the initial customer response toward Velo, a modern pet owner engagement application, was positive. We expect these developments to have strongly favored the segment\u2019s revenues. Story Continues IDEXX Laboratories, Inc. Price and EPS Surprise IDEXX Laboratories, Inc. Price and EPS Surprise IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote Additionally, in the third quarter, the company experienced continued strong growth from its Premium Hematology and SediVue platforms. We expect the trend to have continued in the fourth quarter of 2024, further boosting IDXX\u2019s revenues. Revenues in global rapid assays are also likely to have benefited from higher net price realization. Global lab revenues might have surged due to strong U.S. performance and growth in the international regions. Meanwhile, IDEXX Laboratories\u2019 reference lab, veterinary software and diagnostic imaging revenues are expected to have benefited from a recent acquisition of Greenline software and data platform. The unit\u2019s organic growth might have been led by robust recurring revenues, indicating the benefits of ongoing momentum in cloud-based software placements. The Zacks Consensus Estimate for CAG business revenues implies a decline of 0.04% year over year. Water The segment is likely to have achieved strong organic revenues in the fourth quarter due to increased volumes in the United States and Europe. The Zacks Consensus Estimate for the Water segment\u2019s revenues implies a decline of 9% year over year. Livestock, Poultry and Dairy (\u201cLPD\u201d) The division is likely to have experienced a revenue decline due to reduced swine testing in China and continued lower herd health screening revenues. The Zacks Consensus Estimate indicates a 7.2% year-over-year increase in LPD revenues for the fourth quarter of 2024. What Our Model Says for IDXX Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. However, that is not the case here, as you can see below: Earnings ESP: IDEXX Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). Top Stocks to Consider Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Argenx ARGX has an Earnings ESP of +44.82% and a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The company is expected to release fourth-quarter 2024 results on March 6. The Zacks Consensus Estimate for EPS implies a surge of 196.4% from the year-ago quarter\u2019s reported figure. Arcutis Biotherapeutics ARQT has an Earnings ESP of +7.97% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2024 results on Feb. 25. ARQT\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.46%. Axogen AXGN has an Earnings ESP of +36.36% and a Zacks Rank #2 at present. The company is likely to release fourth-quarter 2024 results on March 4. The Zacks Consensus Estimate for EPS implies a surge of 166.7% from the year-ago quarter\u2019s reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report AxoGen, Inc. (AXGN) : Free Stock Analysis Report argenex SE (ARGX) : Free Stock Analysis Report Arcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-27T14:07:00+00:00", "sentiment": {"score": 0.9425934245809913, "confidence": 0.9577909708023071, "probabilities": {"positive": 0.9577909708023071, "negative": 0.01519754622131586, "neutral": 0.027011534199118614}}, "embedding": [-0.05994525924324989, -0.03097108006477356, 0.08682093769311905, 0.02381853014230728, 0.007666363380849361, -0.04914438724517822, 0.02704285830259323, 0.1209639236330986, 0.1481442004442215, 0.06034059822559357, -0.05052948743104935, 0.10021964460611343, 0.0729956179857254, 0.05513092130422592, -0.14034906029701233, -0.04744527488946915, 0.01466781459748745, -0.030913710594177246, -0.1653972715139389, -0.003323528915643692, -0.05436394736170769, -0.06757824122905731, 0.09643182903528214, -0.06591705232858658, -0.0009091384708881378, -0.04423431679606438, -0.10365870594978333, -0.061568185687065125, -0.05356181412935257, -0.022065846249461174, -0.07390525937080383, 0.17903396487236023, 0.059645991772413254, -0.11373799294233322, -0.049296945333480835, -0.12556426227092743, 0.06019239127635956, 0.013259259052574635, 0.03509483486413956, -0.008592112921178341, 0.01253095455467701, -0.04063262790441513, -0.12226119637489319, -0.016756877303123474, -0.06807811558246613, -0.11382947117090225, -0.04160226881504059, -0.02084430120885372, -0.00390817504376173, 0.07525920122861862, -0.10138396918773651, -0.10742582380771637, 0.10470647364854813, 0.0022495784796774387, -0.06844651699066162, -0.03895740211009979, -0.12158090621232986, -0.06708045303821564, -0.015108080580830574, 0.027490299195051193, 0.016109876334667206, 0.030744746327400208, -0.0046795327216386795, 0.09690496325492859, 0.06859153509140015, 0.028845155611634254, -0.02225862815976143, 0.0607934333384037, -0.14345872402191162, -0.08533056080341339, 0.03907319903373718, -0.07296588271856308, -0.04860888049006462, 0.011665046215057373, -0.006055436097085476, 0.1144690215587616, 0.16587582230567932, 0.06746120750904083, 0.17609786987304688, -0.08964766561985016, 0.04212974011898041, 0.07572657614946365, 0.008499721065163612, -0.05560285598039627, 0.019047506153583527, 0.05884545296430588, 0.11575896292924881, 0.10488864779472351, 0.010085307992994785, 0.03468230366706848, 0.10963782668113708, -0.06421588361263275, -0.07507641613483429, -0.01285559218376875, 0.1612049788236618, -0.027563806623220444, -0.07354938983917236, -0.04224627465009689, 0.169842928647995, 0.033365532755851746, 0.07587067782878876, 0.09723737835884094, -0.053943488746881485, -0.022650979459285736, -0.07142744958400726, -0.1564197689294815, 0.057192545384168625, 0.03434428200125694, 0.05264250189065933, 0.022291328758001328, -0.152596116065979, 0.023588599637150764, -0.00701027549803257, -0.056697141379117966, -0.03607478737831116, 0.14496996998786926, -0.041825734078884125, 0.06301562488079071, 0.1880607306957245, -0.07752115279436111, 0.11815027892589569, 0.008854714222252369, -0.07479070127010345, -0.013874534517526627, 0.016061756759881973, 0.09484758973121643, -0.14901447296142578, 1.1971744339448845e-32, -0.02071860060095787, 0.07834377139806747, -0.027005236595869064, -0.027761319652199745, -0.0017776750028133392, -0.04213684797286987, -0.006015847437083721, 0.014054259285330772, -0.0745411142706871, -0.013083066791296005, -0.2208770364522934, 0.18352416157722473, -0.02564769610762596, -0.009676173329353333, 0.02547592855989933, -0.053370244801044464, -0.015206433832645416, 0.11498133838176727, 0.028194867074489594, 0.02922895923256874, 0.026125513017177582, -0.16263635456562042, 0.03486551716923714, 0.05876055359840393, 0.06840948015451431, 0.13200192153453827, -0.07147439569234848, 0.028767168521881104, -0.04118067026138306, 0.04086708277463913, -0.10703956335783005, -0.08799343556165695, 0.025831038132309914, -0.10604414343833923, -0.1865708827972412, -0.010678939521312714, -0.006717602256685495, -0.07496295124292374, 0.08643890917301178, 0.10075728595256805, 0.009412819519639015, 0.07635825127363205, -0.05399796739220619, -0.12757399678230286, -0.019112760201096535, 0.05919715017080307, -0.0688273087143898, -0.007417346350848675, -0.018207024782896042, 0.06289453059434891, -0.05654526129364967, 0.0555429682135582, 0.027551207691431046, -0.11341597139835358, -0.018211141228675842, 0.03901296481490135, -0.02573905698955059, -0.1422833502292633, -0.06722354143857956, 0.09866966307163239, 0.02889670617878437, 0.20761682093143463, -0.05122750252485275, 0.04727967455983162, -0.07377127557992935, 0.1373329758644104, 0.03474158048629761, 0.017921356484293938, -0.06772419810295105, 0.2630109190940857, -0.025161266326904297, -0.04747593030333519, 0.06568079441785812, -0.14945808053016663, 0.2262616753578186, -0.06919190287590027, -0.06353405863046646, 0.0023160018026828766, 0.10340940207242966, 0.04142279550433159, -0.01668449118733406, 0.12705542147159576, -0.06194579228758812, -0.019040431827306747, 0.0262165330350399, 0.004639200866222382, 0.05164839327335358, 0.17854458093643188, 0.004601753316819668, 0.020787440240383148, 0.039903424680233, -0.05704320967197418, -0.09425710141658783, 0.1534784883260727, -0.012363084591925144, -1.1637577744132962e-32, -0.035879626870155334, 0.12333686649799347, -0.02336212992668152, -0.0679909810423851, -0.09516551345586777, -0.01573946699500084, 0.09047198295593262, 0.04430612549185753, 0.06026289612054825, -0.07804553210735321, 0.03328273817896843, 0.07445120811462402, -0.027047567069530487, 0.16006800532341003, -0.0554644912481308, -0.01858096569776535, -0.029525890946388245, -0.13008129596710205, 0.05422833561897278, -0.03192969039082527, 0.04056452587246895, 0.14390677213668823, -0.09185972809791565, 0.10606299340724945, -0.022729869931936264, 0.0875447541475296, 0.08101177215576172, 0.13770219683647156, 0.07106229662895203, -0.19412408769130707, -0.06374792009592056, -0.06617039442062378, -0.08660336583852768, 0.045854926109313965, -0.011880755424499512, 0.020344702526926994, 0.06121136620640755, -0.1247258111834526, -0.08429775387048721, -0.07737642526626587, 0.03878526762127876, 0.005989338271319866, -0.0343296155333519, 0.06706847995519638, 0.05253724008798599, 0.02581079676747322, 0.06582900881767273, -0.024908797815442085, 0.14044144749641418, 0.06139018386602402, 0.014904961921274662, 0.038037583231925964, -0.046396635472774506, 0.03980960324406624, -0.16512586176395416, -0.002306405920535326, -0.05242320895195007, -0.006821954622864723, -0.2017894685268402, 0.04318823292851448, 0.0019488255493342876, 0.11926274001598358, 0.00989073608070612, 0.13027191162109375, -0.03760756552219391, 0.010320226661860943, 0.09988750517368317, -0.06575769186019897, 0.011164543218910694, -0.12643977999687195, -0.026529205963015556, 0.028361795470118523, -0.058243218809366226, -0.1980171501636505, -0.025926856324076653, 0.18615397810935974, -0.06369777768850327, -0.17763158679008484, -0.03531937301158905, -0.024457000195980072, 0.0018513367976993322, -0.049926452338695526, 0.032345935702323914, 0.010352157056331635, -0.08805295079946518, 0.0919872373342514, -0.018807468935847282, 0.11774832755327225, -0.04139991104602814, -0.01220962405204773, -0.0998518168926239, -0.11315123736858368, -0.16878578066825867, 0.04871557652950287, -0.011470152996480465, -1.011154182606333e-07, 0.03453866392374039, -0.014722205698490143, -0.01773018017411232, -0.0331241711974144, 0.060939788818359375, -0.05554655194282532, -0.030457301065325737, 0.0643841028213501, 0.11422140896320343, 0.12478574365377426, 0.0588180273771286, 0.010932790115475655, -0.15231484174728394, 0.011152027174830437, -0.014078915119171143, 0.020501330494880676, -0.15273481607437134, 0.022319074720144272, -0.014679333195090294, -0.06341418623924255, -0.052571043372154236, 0.1256924569606781, 0.03347496688365936, -0.19525910913944244, 0.03620283305644989, -0.14944031834602356, -0.036517444998025894, 0.020445123314857483, -0.039791595190763474, -0.025942958891391754, -0.03478003665804863, 0.014988282695412636, -0.026279689744114876, -0.008076274767518044, 0.03784501925110817, -0.15302011370658875, 0.04836710914969444, 0.014633530750870705, 0.12899601459503174, 0.09057123214006424, 0.043117016553878784, 0.011490190401673317, -0.06233862042427063, -0.042730413377285004, -0.07628574967384338, -0.08500415086746216, -0.17327970266342163, -0.07862980663776398, 0.10547293722629547, -0.17006529867649078, 0.022970933467149734, -0.03659431263804436, 0.006437309086322784, -0.05718893185257912, 0.04712594673037529, 0.05324059724807739, -0.08417759835720062, -0.09764623641967773, -0.06126159057021141, 0.10414053499698639, 0.08021548390388489, -0.22802600264549255, 0.10191994160413742, 0.040310848504304886], "changes": {"1wk": -7.087720904433937}}, {"text": "Robust Analytical Instruments Segment Likely to Aid TMO's Q4 Earnings Zacks Equity Research Thu, Jan 23, 2025, 3:32 PM 6 min read In This Article: TMO -0.67% Thermo Fisher Scientific Inc. TMO is slated to release fourth-quarter 2024 results on Jan. 30, before market open. See the Zacks Earnings Calendar to stay ahead of market-making news . Thermo Fisher\u2019s third-quarter earnings of $5.28 per share beat the Zacks Consensus Estimate by 0.6%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.63%. TMO\u2019s Q4 Estimates The Zacks Consensus Estimate for revenues is pegged at $11.25 billion, suggesting 3.3% growth from the prior-year quarter\u2019s reported figure. The consensus mark for earnings is pegged at $5.92 per share, indicating 4.4% growth from the year-ago quarter\u2019s reported numbers. Estimate Revision Trend Ahead of Earnings Estimates for Thermo Fisher\u2019s fourth-quarter earnings have remained unchanged at $5.92 per share in the past 30 days. Now, let's look at how things might have progressed for the MedTech major prior to the announcement. Factors at Play Thermo Fisher\u2019s Analytical Instruments segment is expected to have generated strong fourth-quarter sales, banking on its newly launched cutting-edge technologies. The segment is expected to benefit from its electron microscopy business. In the fourth quarter, the company introduced the Thermo Scientific Iliad (Scanning) Transmission Electron Microscope, which integrates a number of TMO\u2019s advanced analytical technologies into a seamless and user-friendly workflow. In the third quarter, the R&D 100 Awards honored Thermo Scientific Orbitrap Astral Mass spectrometer in the market disruptors special recognition category. Additionally, per management, the adoption of Thermo Scientific\u2019s Orbitrap Astral continues to be incredibly strong. We expect these developments to have contributed to TMO\u2019s fourth-quarter revenues. Per our model, Thermo Fisher\u2019s Analytical Instruments business should earn $2.19 billion in revenues, suggesting 7.5% growth year over year. Within the Life-Science Solutions segment, the company is likely to have experienced a sales decline due to the runoff of pandemic-related revenues. In May 2023, WHO declared an end to COVID-19 as a public health emergency. Within this segment, in the third quarter, the company launched the Applied Biosystems MagMAX Sequential DNA/RNA kit, which helps researchers identify unique insights into cancer-causing genetic alterations. Also, TMO introduced Invitrogen Vivofectamine Delivery Solutions, which delivers nucleic acids to multiple targets with therapeutic effects. These developments might have turned in favor of Thermo Fisher in the fourth quarter. Story Continues Meanwhile, the bioproduction business has likely grown in the quarter, banking on strong adoption in the pharma and biotech segment. Within this business, the company introduced Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8, which expanded on Thermo Fisher\u2019s CTS Detachable Dynabeads platform. Meanwhile, TMO is expected to have gained from its successful acquisition of Olink Holding AB during the third quarter. Per our model, the Life-Science Solutions business is expected to have generated $2.65 billion in revenues for the fourth quarter, calling for a 7.5% improvement year over year. The Specialty Diagnostics segment (Clinical Diagnostics business from the molecular controls that go into testing kits) is expected to have gained positive contributions, led by its transplant diagnostics and immunodiagnostics businesses as well as the healthcare market channel. Additionally, during the fourth quarter, the company received approval from the Food and Drug Administration (\u201cFDA\u201d) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with VORANIGO tablets. Thermo Fisher Scientific Inc. Price and EPS Surprise Thermo Fisher Scientific Inc. Price and EPS Surprise Thermo Fisher Scientific Inc. price-eps-surprise | Thermo Fisher Scientific Inc. Quote In the previous quarter, TMO partnered with the National Cancer Institute on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial. The company also launched a pre-transplant risk assessment assay to help assess the risk of early acute rejection in kidney transplant recipients. Moreover, it secured 510(k) FDA clearance for SeCore CDx HLA A Sequencing System for synovial sarcoma. We expect these developments to have had a positive impact on the company\u2019s fourth-quarter top-line performance. Our model projects TMO\u2019s Specialty Diagnostics business to report $1.13 billion in revenues, suggesting 2% growth year over year. Within the Laboratory Products and Services segment, revenues are expected to have increased due to the research and safety market channel. During the fourth quarter, the company introduced Thermo Scientific iCAP MX Series ICP-MS, designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful substances. During the third quarter, the company opened its first electron microscopy demo center, NanoPort, in Taiwan. TMO also expanded its global laboratory services with a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. This, too, while strengthening the company\u2019s foothold in Taiwan, might have had a favorable impact on TMO\u2019s top line in the to-be-reported quarter. Our model expects TMO\u2019s Laboratory Products and Services business\u2019 fourth-quarter revenues to be $5.72 billion, flat year over year. What Our Quantitative Model Predicts Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Thermo Fisher has an Earnings ESP of +0.65%. You can uncover the best stocks to buy or sell before they\u2019re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4. Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Argenx ARGX has an Earnings ESP of +44.82% and a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here. The company is expected to release fourth-quarter 2024 results on March 6. The Zacks Consensus Estimate for EPS implies a surge of 196.4% from the year-ago quarter\u2019s reported figure. Arcutis Biotherapeutics ARQT has an Earnings ESP of +7.97% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2024 results on Feb. 25. ARQT\u2019s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.46%. Axogen AXGN has an Earnings ESP of +36.36% and a Zacks Rank #2 at present. The company is likely to release fourth-quarter 2024 results on March 4. The Zacks Consensus Estimate for EPS implies a surge of 166.7% from the year-ago quarter\u2019s reported figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report AxoGen, Inc. (AXGN) : Free Stock Analysis Report argenex SE (ARGX) : Free Stock Analysis Report Arcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-23T12:32:00+00:00", "sentiment": {"score": 0.8483659252524376, "confidence": 0.8958554863929749, "probabilities": {"positive": 0.8958554863929749, "negative": 0.04748956114053726, "neutral": 0.05665487423539162}}, "embedding": [-0.14519919455051422, 0.04097053408622742, -0.0536869540810585, 0.000384477898478508, -0.0881170779466629, -0.08496042340993881, -0.04785735160112381, 0.20091871917247772, 0.1283428966999054, 0.17138370871543884, -0.05176885798573494, -0.0204789899289608, -0.0037642773240804672, 0.055654652416706085, -0.07460879534482956, 0.017525311559438705, 0.05643501877784729, -0.08214424550533295, -0.01404169574379921, -0.00799448974430561, -0.04189445823431015, 0.007287983782589436, 0.11729675531387329, -0.06519424170255661, 0.1386510282754898, 0.017743848264217377, -0.08162812888622284, 0.015111152082681656, -0.15391720831394196, 0.0807657539844513, -0.21532922983169556, 0.1844184249639511, 0.0962982103228569, -0.022478433325886726, -0.059607889503240585, -0.0683455765247345, -0.07059434801340103, 0.009116258472204208, 0.13944289088249207, 0.009785467758774757, -0.005254167597740889, -0.002180779352784157, -0.0785786360502243, -0.055403441190719604, -0.08498437702655792, -0.12816454470157623, 0.15907806158065796, -0.024313773959875107, -0.029367830604314804, 0.1116015762090683, -0.1714930534362793, -0.04767701402306557, 0.07817958295345306, 0.0791822224855423, -0.10711798071861267, 0.03118460439145565, -0.008136535063385963, -0.08137018978595734, 0.04496002942323685, 0.06097516417503357, -0.05001060292124748, -0.02342318370938301, -0.10442432761192322, 0.11707796156406403, 0.20194631814956665, -0.05965393781661987, -0.021059244871139526, 0.02640474960207939, -0.1647472381591797, 0.008282873779535294, 0.06591171026229858, -0.013972276821732521, 0.027643177658319473, -0.07737929373979568, -0.05715000256896019, 0.06189022213220596, 0.20620006322860718, 0.05529441684484482, 0.21368879079818726, -0.09725084155797958, 0.12955915927886963, -0.08749822527170181, -0.1199822947382927, -0.05585117265582085, -0.11322694271802902, 0.027911853045225143, 0.0715445876121521, 0.1591861993074417, 0.10916303098201752, 0.024134859442710876, 0.06583123654127121, -0.05357125401496887, -0.12712503969669342, -0.10579067468643188, 0.017506219446659088, -0.006124481558799744, -0.055086780339479446, 0.008933966979384422, 0.18675172328948975, 0.023780670017004013, 0.05812164023518562, 0.060651738196611404, 0.0008377665653824806, -0.033343490213155746, -0.01754099316895008, -0.08611468970775604, 0.13486745953559875, -0.018764454871416092, 0.11603483557701111, 0.048516154289245605, -0.11164453625679016, 0.07307595014572144, -0.053685396909713745, -0.013375984504818916, -0.015032598748803139, 0.008658692240715027, -0.007132150698453188, 0.15409067273139954, 0.15282130241394043, 0.08393226563930511, 0.10109849274158478, 0.055170938372612, -0.0024701054207980633, 0.038589537143707275, 0.05763786658644676, 0.06079770252108574, -0.15537436306476593, 7.909478308716877e-33, 0.05028710514307022, 0.11279672384262085, -0.012017006985843182, -0.04113539680838585, 0.02661564201116562, 0.051625121384859085, -0.0381021574139595, 0.040949512273073196, -0.07225440442562103, -0.05161447823047638, -0.1517564356327057, 0.1418488472700119, -0.08573158085346222, 0.01146228238940239, 0.09555979818105698, 0.004888149909675121, -0.07544874399900436, 0.04933718591928482, -0.01812184415757656, -0.03047599457204342, -0.03732828050851822, -0.08087195456027985, -0.00647879671305418, 0.18891242146492004, 0.04053995758295059, 0.18696318566799164, -0.010939983651041985, 0.019062384963035583, -0.1686612367630005, 0.07784920185804367, -0.005104602314531803, 0.030140116810798645, -0.010197347961366177, -0.21367719769477844, 0.05564587935805321, -0.09203040599822998, -0.06577379256486893, 0.006658222526311874, 0.1696297824382782, 0.05009814724326134, -0.03233002871274948, 0.09000617265701294, -0.09105837345123291, -0.08569908887147903, -0.0991862416267395, 0.018268462270498276, -0.026970168575644493, 0.02484925463795662, 0.12520596385002136, 0.012285163626074791, -0.057411789894104004, -0.04464353993535042, -0.0016333232633769512, -0.16860146820545197, -0.015663500875234604, -0.002299301326274872, -0.07179966568946838, -0.12810273468494415, 0.09878090023994446, 0.09656110405921936, -0.04555349051952362, 0.1753770411014557, 0.005556732416152954, 0.012349816039204597, -0.09006672352552414, 0.24283155798912048, 0.020016897469758987, -0.011728430166840553, 0.018340669572353363, 0.12574025988578796, -0.08727124333381653, -0.04927636310458183, 0.06173748895525932, -0.12630997598171234, 0.1146634966135025, -0.003059722250327468, 0.029009275138378143, -0.06364944577217102, 0.11596080660820007, -0.03452158346772194, -0.0157113466411829, -0.06429638713598251, 0.0915881097316742, -0.08783906698226929, -0.009648655541241169, -0.07824379205703735, -0.027950052171945572, 0.055231258273124695, -0.002218589186668396, -0.05005703866481781, 0.09940992295742035, -0.1348573863506317, -0.12871405482292175, 0.11171823740005493, -0.049602411687374115, -9.17190340551835e-33, -0.13090947270393372, 0.0691467747092247, -0.09976992756128311, -0.029381610453128815, -0.10813126713037491, -0.03598376736044884, 0.02456670068204403, 0.0669836774468422, 0.047254882752895355, -0.04480784386396408, 0.029538430273532867, 0.10709390044212341, -0.09126332402229309, -0.05132445693016052, -0.015037414617836475, 0.04276905208826065, 0.010722268372774124, -0.1067030057311058, 0.0009988239035010338, -0.05509588494896889, 0.11603868007659912, 0.09370282292366028, -0.05015520006418228, 0.06486817449331284, 0.04167404770851135, 0.10306590795516968, -0.017146065831184387, -0.0006931624375283718, 0.05704255402088165, -0.007630571722984314, -0.06450745463371277, -0.1523900330066681, -0.05719951540231705, 0.00514967879280448, 0.05224046856164932, -0.01834518276154995, 0.09312267601490021, -0.10530313104391098, 0.06268839538097382, -0.08357970416545868, 0.2410653829574585, 0.015172853134572506, 0.060642972588539124, -0.05006954073905945, -0.012662289664149284, -0.012272590771317482, 0.028660744428634644, -0.03145629167556763, 0.0919458195567131, 0.05584621801972389, 0.04094765707850456, 0.00022637192159891129, -0.04872092604637146, -0.037253234535455704, -0.10142484307289124, 0.022287864238023758, -0.010067857801914215, -0.031754303723573685, -0.12980155646800995, -0.011157018132507801, 0.008218372240662575, 0.049852386116981506, 0.030571602284908295, 0.054512184113264084, -0.052460163831710815, 0.07337084412574768, 0.09027045220136642, -0.037142738699913025, 0.0507962740957737, -0.095467209815979, 0.022509168833494186, -0.06424169987440109, 0.0702115073800087, -0.2824576497077942, -0.05504418909549713, 0.22587957978248596, -0.050522930920124054, -0.17687635123729706, -0.00969769898802042, -0.011761855334043503, -0.026395006105303764, 0.09997731447219849, 0.09860583394765854, -0.00307389535009861, 0.00504043884575367, 0.02131897211074829, 0.05292706936597824, -0.01930566504597664, -0.13970178365707397, -0.006399830803275108, -0.03710591793060303, -0.1420678049325943, -0.04742751270532608, 0.052100054919719696, 0.0913214236497879, -1.0065624422850306e-07, 0.10845452547073364, -0.027378853410482407, 0.03456903249025345, -0.06350850313901901, 0.17171043157577515, -0.08152750134468079, -0.017428148537874222, 0.10205289721488953, 0.16390478610992432, 0.15510044991970062, 0.07229699939489365, 0.02348797582089901, -0.11325733363628387, 0.05160737782716751, -0.02946741320192814, 0.005918397568166256, -0.1261964589357376, -0.03303690627217293, -0.13619321584701538, -0.14497245848178864, 0.0004277462139725685, 0.0026431609876453876, 0.06217503920197487, -0.1653728187084198, 0.053067758679389954, -0.03940395265817642, -0.17463615536689758, -0.009452784433960915, 0.01166144572198391, 0.01414402574300766, -0.05784006789326668, -0.04677343741059303, -0.04496610537171364, 0.09543217718601227, -0.011971916072070599, -0.1678369641304016, -0.0005271770060062408, -0.03721964359283447, 0.047904472798109055, 0.10325181484222412, 0.019519343972206116, -0.008196970447897911, -0.030254218727350235, 0.08557700365781784, -0.09642007201910019, -0.039897069334983826, -0.17350704967975616, -0.014542820863425732, 0.00863716658204794, -0.04801556095480919, 0.0781814232468605, -0.002635633572936058, -0.12067126482725143, -0.06083517521619797, -0.04909498244524002, 0.02904810756444931, -0.011195948347449303, -0.05605066567659378, -0.1562952995300293, -0.04187272489070892, 0.11970019340515137, -0.2640882134437561, 0.00386182963848114, 0.012751966714859009], "changes": {"1wk": 0.8823520749498234}}, {"text": "Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade Zacks Equity Research Thu, Jan 16, 2025, 5:55 PM 4 min read In This Article: ARQT -4.15% Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $13.92, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.13 indicates a 37.4% upside potential. The mean estimate comprises eight short-term price targets with a standard deviation of $4.79. While the lowest estimate of $12 indicates a 13.8% decline from the current price level, the most optimistic analyst expects the stock to surge 108.3% to reach $29. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside in ARQT. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside. Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts. However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces. Story Continues That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Here's Why There Could be Plenty of Upside Left in ARQT Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 8.9%, as one estimate has moved higher compared to no negative revision. Moreover, ARQT currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ARQT could gain, the direction of price movement it implies does appear to be a good guide. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Arcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-16T14:55:14+00:00", "sentiment": {"score": 0.004595860838890076, "confidence": 0.1307176798582077, "probabilities": {"positive": 0.1307176798582077, "negative": 0.12612181901931763, "neutral": 0.7431604862213135}}, "embedding": [0.008069617673754692, 0.014841738156974316, -0.03957054018974304, 0.13031548261642456, -0.00933932140469551, 0.03232927620410919, -0.04502880573272705, 0.12796740233898163, 0.13511840999126434, -0.013845033012330532, -0.1298695206642151, 0.02200126461684704, 0.039890654385089874, -0.0722021758556366, -0.022551368921995163, -0.053256019949913025, 0.10675743222236633, -0.08618007600307465, -0.10194316506385803, 0.12782514095306396, -0.17177727818489075, -0.05956059694290161, -0.0713709145784378, 0.008661381900310516, 0.03368208557367325, -0.08734476566314697, -0.009797708131372929, -0.07581004500389099, -0.14571250975131989, -0.053136732429265976, -0.055457860231399536, 0.06116817891597748, 0.15621986985206604, 0.0024565747007727623, -0.015995513647794724, -0.04821954667568207, -0.04594486206769943, 0.10731382668018341, 0.1466015875339508, 0.10732656717300415, -0.0018568122759461403, 0.06872826814651489, -0.1398518830537796, 0.008136563003063202, 0.03493907302618027, -0.13430379331111908, 0.05376514419913292, -0.03123336099088192, -0.07329414039850235, 0.051806531846523285, -0.17346036434173584, 0.044784437865018845, -0.022434581071138382, -0.03433460742235184, -0.04399191588163376, 0.07170937955379486, -0.06600181758403778, 0.013260780833661556, 0.14678944647312164, 0.054438307881355286, 0.028611384332180023, -0.01870841719210148, 0.025557927787303925, -0.019299279898405075, 0.18898159265518188, -0.08435605466365814, 0.027385801076889038, 0.030147233977913857, -0.01710810884833336, 0.06003381311893463, 0.12055568397045135, 0.019962765276432037, -0.130360946059227, -0.06127134710550308, 0.019040608778595924, 0.13852956891059875, -0.010351616889238358, 0.029657108709216118, 0.051782675087451935, -0.08002947270870209, 0.05473779886960983, -0.07516923546791077, -0.11576351523399353, -0.023308299481868744, 0.09446395188570023, -0.033109866082668304, 0.10579501837491989, 0.026569746434688568, 0.058089278638362885, 0.008801650255918503, 0.10230587422847748, -0.16509604454040527, -0.06456618010997772, -0.003591880202293396, 0.17453229427337646, -0.007548642344772816, -0.01634805276989937, -0.06476008147001266, -0.10202660411596298, -0.013354956172406673, 0.12960338592529297, 0.01413239911198616, -0.0368446446955204, 0.01927725411951542, -0.06705363094806671, -0.15624499320983887, 0.03995371237397194, -0.07562819123268127, 0.011954556219279766, -0.0008055185899138451, -0.0821995884180069, -0.010451060719788074, -0.08552093058824539, -0.09232884645462036, -0.010617045685648918, -0.029772713780403137, -0.030842185020446777, -0.06130209565162659, -0.037460651248693466, -0.02181529626250267, 0.0035805627703666687, 0.05193765461444855, 0.07997298985719681, 0.04784560948610306, 0.03165726363658905, 0.03772086277604103, -0.1713637113571167, 1.2107559487374914e-32, 0.02288592979311943, 0.06778977066278458, -0.05547212064266205, -0.20006370544433594, -0.07722266763448715, -0.024082601070404053, 0.025717718526721, -0.058236733078956604, 0.04024626687169075, 0.03750869259238243, -0.01084381714463234, 0.12015137076377869, 0.016520829871296883, 0.03359811007976532, -0.010416774079203606, -0.013345190323889256, -0.005036210175603628, 0.008786572143435478, -0.07629731297492981, -0.009913638234138489, -0.022207356989383698, 0.08639262616634369, -0.13142690062522888, -0.060850948095321655, -0.05842337757349014, -0.09676710516214371, -0.033031899482011795, 0.07879112660884857, -0.12689265608787537, 0.024136323481798172, -0.0208060871809721, 0.07235343754291534, 0.051059529185295105, -0.08561304211616516, -0.012357715517282486, -0.10858931392431259, -0.06192565709352493, -0.0356828048825264, 0.07829849421977997, 0.0007759570144116879, -0.01605101116001606, 0.15362411737442017, -0.03887798264622688, -0.028009653091430664, 0.10948404669761658, -0.00725402869284153, -0.11254563182592392, -0.040208395570516586, -0.13852736353874207, -0.0819561779499054, -0.07070382684469223, 0.0531390979886055, -0.02611985243856907, -0.014848804101347923, -0.04444926977157593, 0.009064387530088425, -0.04301118105649948, -0.16734445095062256, 0.06003960222005844, 0.09567556530237198, 0.012790504842996597, 0.10731953382492065, -0.04368007183074951, -0.013954013586044312, -0.18419605493545532, 0.25869426131248474, 0.032726842910051346, 0.14963741600513458, -0.047260504215955734, 0.1379767805337906, 0.06383735686540604, -0.026813270524144173, 0.031451866030693054, -0.1011480838060379, 0.049141623079776764, -0.0791035145521164, -0.020074162632226944, 0.13612988591194153, 0.10580241680145264, -0.10422365367412567, 0.016225669533014297, 0.016262155026197433, 0.15711820125579834, -0.06665924191474915, -0.033616866916418076, -0.08526116609573364, -0.04746216535568237, -0.008446413092315197, -0.0951588898897171, 0.07637381553649902, 0.11592532694339752, 0.05631208419799805, -0.15180927515029907, 0.19058872759342194, 0.019408728927373886, -1.1088942204509553e-32, -0.08950082957744598, -0.04414644092321396, -0.056859686970710754, 0.0015579946339130402, -0.06828279048204422, 0.03129510208964348, 0.031138675287365913, -0.03917509317398071, 0.010476991534233093, -0.07798995822668076, -0.0841381698846817, 0.011615012772381306, -0.1284363716840744, 0.059464819729328156, 0.02072199434041977, -0.027723638340830803, 0.09801147878170013, -0.07972609996795654, 0.04417497664690018, -0.023222673684358597, -0.0775265097618103, -0.011529697105288506, -0.10430595278739929, 0.08633748441934586, 0.06812906265258789, 0.06000091880559921, 0.08044558018445969, -0.023129383102059364, 0.009113654494285583, -0.10585269331932068, -0.08248835802078247, -0.008052709512412548, -0.1235545426607132, 0.04291171580553055, -0.0191718190908432, 0.10044954717159271, 0.01639796793460846, -0.058551810681819916, -0.09121540188789368, -0.024212509393692017, 0.06282828748226166, -0.01967596262693405, 0.04549486190080643, -0.0653960108757019, 0.07112574577331543, 0.06058333441615105, 0.15919502079486847, 0.040939122438430786, 0.08519037067890167, 0.04815613478422165, 0.10743245482444763, 0.02286296896636486, 0.0809050053358078, 0.18730810284614563, -0.07785843312740326, -0.055411264300346375, -0.01528710313141346, 0.0864761471748352, 0.02965281531214714, 0.04602012038230896, 0.0753316581249237, 0.1403425633907318, 0.0366368293762207, -0.0774371325969696, 0.015522127039730549, 0.07743294537067413, -0.060822002589702606, -0.025362033396959305, -0.028222201392054558, -0.07683786004781723, -0.005893049295991659, -0.08872240781784058, 0.10003913938999176, -0.02018899843096733, -0.06563424319028854, 0.10461293160915375, -0.06572066992521286, -0.1491069793701172, -0.033307239413261414, 0.0669156014919281, -0.009373024106025696, 0.08606938272714615, -0.02729092352092266, -0.027951857075095177, -0.03915756940841675, 0.03545525670051575, -0.0919448509812355, 0.10782606899738312, -0.0743187665939331, 0.11611251533031464, -0.044770725071430206, -0.1696574091911316, -0.05109882727265358, -0.04002673551440239, -0.03140636533498764, -1.002632501467815e-07, -0.04459463059902191, -0.003212778130546212, 0.031573645770549774, 0.005767677444964647, 0.03477448970079422, -0.04933502525091171, 0.019696438685059547, -0.05504818633198738, 0.0792747363448143, 0.10505950450897217, 0.16208118200302124, 0.017561806365847588, -0.19556653499603271, 0.1015298068523407, -0.12862589955329895, 0.02975725755095482, -0.09165070950984955, -0.05685225501656532, 0.05873199924826622, -0.0030839014798402786, 0.07090340554714203, 0.03784758597612381, -0.006582885980606079, -0.03979791700839996, 0.13114133477210999, -0.0234769769012928, -0.09649966657161713, 0.0983210951089859, -0.009041722863912582, 0.026757704094052315, 0.0379917249083519, -0.06426132470369339, 0.10121087729930878, 0.00989584345370531, 0.12794840335845947, 0.07100197672843933, 0.09978817403316498, 0.04637862741947174, 0.10100095719099045, 0.04942489415407181, -0.058269109576940536, 0.0245297159999609, -0.008135512471199036, -0.033776942640542984, 0.007228061556816101, -0.05802711844444275, -0.17507165670394897, 0.07450985908508301, 0.03216037526726723, -0.13341642916202545, 0.10589480400085449, -0.06608307361602783, 0.12485582381486893, 0.0729757770895958, 0.07815101742744446, -0.0022905883379280567, -0.057515569031238556, -0.07094874978065491, -0.1290784329175949, 0.042368993163108826, 0.10491040349006653, -0.1623496115207672, -0.016917310655117035, 0.21991950273513794], "changes": {"1wk": -1.0909063165838067}}, {"text": "PREMIUM Arcutis Biotherapeutics Expects Fiscal Q4 Revenue to Soar Driven by Zoryve Demand MT Newswires Mon, Jan 13, 2025, 12:07 PM In This Article: ARQT -4.15% Arcutis Biotherapeutics (ARQT) said Sunday its preliminary fiscal Q4 revenue is expected to increase PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-13T09:07:05+00:00", "sentiment": {"score": 0.2147350935265422, "confidence": 0.2236419916152954, "probabilities": {"positive": 0.2236419916152954, "negative": 0.008906898088753223, "neutral": 0.7674511075019836}}, "embedding": [-0.12134244292974472, -0.047685690224170685, -0.061715640127658844, 0.0034781217109411955, 0.049966588616371155, 0.034375518560409546, -0.0021129439119249582, 0.06670692563056946, 0.03741934150457382, 0.09860260784626007, 0.04308083653450012, 0.06595613807439804, 0.07589180022478104, 0.1081240102648735, 0.022364338859915733, 0.0026756718289107084, 0.11192497611045837, -0.15794861316680908, 0.017232103273272514, -0.022608939558267593, -0.07434363663196564, -0.006022607441991568, 0.03868067264556885, -0.1117648184299469, 0.1459828019142151, -0.1258416771888733, -0.23205327987670898, -0.06317511945962906, -0.08811745792627335, -0.10043159127235413, -0.020065881311893463, 0.0331694670021534, 0.09991619735956192, -0.15292654931545258, 0.1422334462404251, -0.09167874604463577, 0.010236816480755806, -0.005220236722379923, -0.07417812943458557, 0.15542472898960114, 0.05072978138923645, -0.09346175193786621, -0.2423790693283081, 0.0693523958325386, 0.06963443756103516, 0.017834775149822235, 0.0340200737118721, -0.0012049599317833781, 0.02072516828775406, 0.0625370517373085, -0.1033441498875618, -0.07892517745494843, -0.0018819676479324698, 0.01575489342212677, -0.030230237171053886, -0.005299419164657593, -0.16331835091114044, -0.026695016771554947, -0.04119185358285904, -0.016169849783182144, 0.022563988342881203, -0.10078554600477219, -0.06587618589401245, 0.11027143895626068, -0.07916758954524994, 0.02386019006371498, 0.08446387946605682, 0.1681101769208908, -0.04596414044499397, -0.13073666393756866, -0.11083392053842545, -0.004403228871524334, -0.09522475302219391, 0.020197149366140366, 0.10432251542806625, 0.20926183462142944, 0.09372714161872864, 0.08483439683914185, 0.049633514136075974, -0.1616019606590271, 0.05145147070288658, -0.005943430121988058, 0.015901848673820496, -0.0584537573158741, 0.11530860513448715, 0.11304895579814911, -0.020759474486112595, -0.12973178923130035, -0.12796814739704132, -0.08931923657655716, 0.24549783766269684, -0.06578271090984344, 0.09787808358669281, -0.01959940232336521, -0.157113179564476, -0.0248725526034832, -0.03674883395433426, -0.22254133224487305, 0.017405081540346146, 0.03229304030537605, 0.09934132546186447, -0.022618774324655533, -0.05180709436535835, -0.01078213844448328, -0.02165929414331913, -0.1376846879720688, 0.06442298740148544, 0.19679361581802368, 0.03272930160164833, 0.1199946179986, -0.018805738538503647, 0.07516582310199738, 0.030971234664320946, -0.18977497518062592, -0.06715355813503265, 0.35017433762550354, -0.10674701631069183, 0.0031520628836005926, 0.006523506250232458, -0.03135215863585472, 0.01751374825835228, 0.06565140187740326, -0.05190502107143402, -0.05695652961730957, 0.03915557265281677, 0.05575373023748398, -0.09191183745861053, 1.6716130640179786e-32, 0.013794721104204655, 0.1932353973388672, 0.11656668782234192, -0.12249103933572769, -0.04846898466348648, 0.04669385775923729, 0.18625614047050476, -0.10805188864469528, -0.03135492652654648, -0.15266886353492737, -0.13692151010036469, 0.1453942209482193, -0.02530151791870594, 0.1016453430056572, -0.13044272363185883, -0.09865368157625198, -0.27187380194664, 0.03728294000029564, 0.13160572946071625, 0.09604872018098831, 0.002954761730507016, -0.06509515643119812, -0.12059894949197769, 0.041365254670381546, 0.03280162438750267, 0.11583992093801498, 0.1637793779373169, -0.06877891719341278, 0.09680792689323425, 0.14170491695404053, -0.17749425768852234, 0.07142031937837601, -0.01196195837110281, -0.225454643368721, -0.10050424188375473, 0.05949646607041359, -0.06344309449195862, -0.06366089731454849, 0.03288910910487175, -0.09590628743171692, -0.04488068073987961, -0.008020495064556599, -0.00947263091802597, -0.11616675555706024, -0.010108638554811478, -0.00963213387876749, -0.013979313895106316, 0.024249328300356865, -0.049136482179164886, -0.07410674542188644, -0.08716700971126556, 0.004063790664076805, -0.03632526844739914, 0.06755247712135315, -0.03451867401599884, 0.046291083097457886, -0.014859193935990334, -0.1075773760676384, 0.03360997140407562, -0.07350928336381912, 0.28145021200180054, 0.014185197651386261, -0.039420291781425476, 0.04373238980770111, -0.21481098234653473, 0.21045328676700592, -0.0018586141522973776, -0.1334863305091858, -0.030579272657632828, 0.3486424386501312, 0.14132936298847198, -0.11804722994565964, 0.03066679649055004, -0.035784266889095306, 0.06504225730895996, -0.04573456570506096, -0.11265275627374649, 0.09950615465641022, 0.14789707958698273, 0.021568575873970985, -0.0907132476568222, 0.0009190406417474151, 0.1386777013540268, 0.02268151193857193, 0.15654389560222626, -0.06466416269540787, 0.14681927859783173, 0.06171416491270065, 0.08450442552566528, 0.05947594344615936, 0.08628548681735992, -0.00046519970055669546, -0.1528010368347168, 0.19351167976856232, -0.05618124082684517, -1.5423890598537645e-32, 0.029583634808659554, 0.14818698167800903, -0.10028406232595444, -0.024511145427823067, -0.20048552751541138, 0.052889373153448105, -0.04903789982199669, 0.1022334098815918, 0.10438533127307892, 0.047280095517635345, 0.06912459433078766, 0.13777707517147064, -0.11148115992546082, 0.023550452664494514, 0.07293152809143066, -0.039163995534181595, 0.007372024469077587, -0.30232545733451843, -0.01619936153292656, 0.1577756106853485, -0.13643264770507812, 0.0018793988274410367, -0.0602194219827652, 0.14048036932945251, 0.171676367521286, -0.02810577116906643, 0.1258736401796341, 0.06747058779001236, 0.10213422030210495, -0.11167251318693161, -0.12179721891880035, -0.27319514751434326, -0.3120025098323822, -0.15758927166461945, -0.07838277518749237, -0.028686679899692535, 0.20533791184425354, 0.08013170957565308, -0.2020464688539505, -0.013260649517178535, 0.13110795617103577, -0.1930740773677826, -0.07185983657836914, 0.09714936465024948, 0.1057836040854454, -0.029017243534326553, 0.012758099474012852, -0.03687553480267525, 0.11819243431091309, 0.025406360626220703, 0.1446588635444641, 0.03008100762963295, 0.12105055153369904, 0.15882204473018646, -0.21216048300266266, 0.05285638943314552, 0.05762650817632675, 0.13446155190467834, -0.14177072048187256, -0.040377695113420486, 0.004043677356094122, 0.11575566977262497, -0.1424182802438736, -0.08761116862297058, 0.0847787857055664, 0.018620144575834274, 0.1767989695072174, -0.06995458900928497, -0.06418093293905258, -0.1804954707622528, 0.017207466065883636, -0.16489647328853607, 0.01021314226090908, -0.172020822763443, -0.0026188420597463846, 0.19383865594863892, -0.11312559992074966, -0.0963003858923912, -0.07223529368638992, -0.0010670509655028582, -0.0008541076676920056, 0.004783171229064465, 0.009970618411898613, -0.0516054630279541, -0.13352350890636444, -0.15818634629249573, 0.10551431775093079, 0.01968635804951191, -0.07517789304256439, 0.10351532697677612, -0.14102999866008759, 0.003382566384971142, -0.08983217179775238, 0.160474494099617, 0.028661401942372322, -1.0053568644252664e-07, 0.18928207457065582, 0.1003994569182396, -0.01847979612648487, 0.10837390273809433, -0.05415789410471916, -0.14876551926136017, -0.1067446693778038, 0.1689707636833191, 0.03278389945626259, 0.11785831302404404, 0.09006055444478989, 0.12397492676973343, 0.01729618012905121, 0.05172007903456688, 0.06440173834562302, 0.13048714399337769, -0.06358937919139862, 0.0012358122039586306, -0.02297312021255493, -0.18882529437541962, -0.05481831729412079, 0.10518234223127365, 0.018180297687649727, -0.1134616956114769, 0.013224609196186066, 0.05084853991866112, 0.07617814093828201, -0.10214604437351227, 0.1906479150056839, -0.13550113141536713, 0.018839286640286446, -0.0007585363928228617, -0.0396404005587101, -0.07346038520336151, -0.12348965555429459, -0.04262898862361908, -0.04502272978425026, -0.0830526202917099, 0.14222915470600128, 0.07593701034784317, -0.06896618753671646, -0.08494241535663605, -0.02693791128695011, 0.04223879799246788, -0.10345820337533951, 0.013187293894588947, -0.26851075887680054, -0.19601204991340637, 0.15588721632957458, -0.04299195483326912, -0.028804752975702286, -0.10932444781064987, 0.18537810444831848, -0.1209801584482193, -0.002783773932605982, 0.09283480048179626, 0.1063447967171669, -0.1016671285033226, -0.04417743161320686, 0.0678882971405983, 0.1863466203212738, -0.2910900413990021, 0.17683400213718414, 0.15215808153152466], "changes": {"1wk": -6.969917837774753}}, {"text": "Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million Arcutis Biotherapeutics, Inc. Sun, Jan 12, 2025, 4:30 PM 5 min read In This Article: ARQT -4.15% Arcutis Biotherapeutics, Inc. Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024 Preliminary unaudited product revenue for the full-year 2024 is expected to be approximately $160 million, up approximately 449% vs. 2023 Robust unit growth across the portfolio with gross-to-net (GTN) similar to prior quarter Preliminary unaudited cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024 are expected to be approximately $229 million Company to release complete fourth quarter and full year 2024 financial results and host a conference call and webcast on February 25, 2025 at 4:30 p.m. EST WESTLAKE VILLAGE, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced certain preliminary unaudited financial information for the fourth quarter and full-year 2024. Preliminary Fourth Quarter and Full-Year 2024 Financial Information Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, representing growth of approximately 366% as compared to the fourth quarter of 2023 and approximately 41% as compared to the third quarter of 2024. Preliminary unaudited product revenue for the full-year 2024 is expected to be approximately $160 million, representing growth of approximately 449% vs. 2023 Revenue growth in the fourth quarter across the franchise was driven by strong demand for all ZORYVE \u00ae (roflumilast) indications, while GTN was similar to the prior quarter Preliminary cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2024 are expected to be approximately $229 million As previously reported, the Company repaid $100 million of its long-term debt held by SLR Investment Corp. and has the option to re-draw approximately $100 million by the first half of 2026 making total liquidity as of December 31, 2024 from cash, cash equivalents, restricted cash, marketable securities, and available debt equal to approximately $329 million \u201cWe are excited by the significant sales momentum and robust revenue growth we continue to generate in our business, driven by expanding demand for our entire ZORYVE franchise,\u201d said Frank Watanabe, president and chief executive officer of Arcutis. \u201cWe anticipate sustained ZORYVE sales growth throughout 2025 as our multiple product launches gain further traction and we secure new approvals, expand insurance coverage, and broaden access to primary care and pediatric practices through our commercial partnership with Kowa.\u201d Story Continues Management will host in-person investor meetings in San Francisco, CA, around the 43 rd Annual J.P. Morgan Healthcare Conference , being held January 13-16, 2025 . Arcutis has not completed preparation of its financial statements for the fourth quarter or full-year 2024. The financial information as of and for the fourth quarter and full-year 2024 presented in this release are preliminary and unaudited and are subject to the close of the quarter and year, completion of our quarter-end and year-end closing procedures, and further financial review. Our independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to this financial information. Our actual results may differ from these estimates as a result of the completion of our quarter-end and year-end closing procedures, review adjustments, and other developments that may arise between now and the time our financial results for the fourth quarter and full year are finalized. Arcutis will report complete fourth quarter and full-year 2024 financial results and provide a business update on Tuesday, February 25, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. EST. A live webcast of the call and the presentation materials will be available on the \u201c Events \u201d section of the Company\u2019s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call. About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis\u2019 dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn , Facebook , Instagram , and X . Forward-Looking Statements Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements which include, but are not limited to, statements regarding commercial execution, regulatory timelines, progress on product access and adoption, and preliminary unaudited financial information as of and for the fourth quarter and full-year 2024. These statements are based on the Company\u2019s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the \u201cRisk Factors\u201d section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contacts Media Amanda Sheldon, Head of Corporate Communications media@arcutis.com Investors Latha Vairavan, Vice President, Finance and Corporate Controller ir@arcutis.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-12T13:30:00+00:00", "sentiment": {"score": 0.907593872398138, "confidence": 0.9210518598556519, "probabilities": {"positive": 0.9210518598556519, "negative": 0.01345798745751381, "neutral": 0.06549020856618881}}, "embedding": [-0.10434982180595398, -0.12556925415992737, -0.09265132248401642, -0.028489410877227783, -0.12208687514066696, -0.06647994369268417, -0.018461503088474274, 0.23362255096435547, 0.10618003457784653, 0.14297473430633545, -0.035205110907554626, -0.002083729486912489, 0.020379628986120224, 0.0771784633398056, -0.10660858452320099, -0.030588265508413315, 0.09565699845552444, -0.06880199164152145, -0.039922233670949936, 0.0900687649846077, 0.030572054907679558, -0.011501556262373924, 0.02800624631345272, -0.009373340755701065, 0.036237478256225586, -0.08480027318000793, -0.12056565284729004, -0.13251027464866638, -0.20667026937007904, -0.09338617324829102, 0.0161723755300045, 0.05634491890668869, 0.10039670020341873, -0.09260861575603485, 0.10150057077407837, 0.010829501785337925, -0.000985479447990656, 0.05924056097865105, 0.05268608778715134, 0.06398259103298187, -0.07469195127487183, -0.07361911237239838, -0.1590479016304016, 0.022213611751794815, 0.08374810218811035, -0.08830958604812622, -0.017536047846078873, 0.027915198355913162, 0.019732976332306862, 0.22443325817584991, -0.08596421778202057, -0.010308077558875084, -0.0018289904110133648, 0.10613399744033813, -0.05230008065700531, -0.0010173883056268096, -0.15438249707221985, -0.05390111356973648, -0.038921065628528595, 0.08129769563674927, 0.007450719363987446, -0.1357315480709076, 0.008946126326918602, -0.029629424214363098, 0.042540308088064194, 0.029704704880714417, 0.061639510095119476, -0.02302710711956024, -0.017493825405836105, -0.036999933421611786, 0.0875072106719017, -0.0917326956987381, -0.1348784863948822, 0.10091111063957214, -0.01718083769083023, 0.20223468542099, 0.15979325771331787, 0.22068659961223602, 0.08014591038227081, -0.1015188992023468, 0.15819674730300903, 0.12369285523891449, 0.012173397466540337, -0.02336023561656475, -0.02785925567150116, 0.09026447683572769, 0.0890093445777893, 0.14584818482398987, 0.03650271147489548, 0.023368123918771744, 0.0878426656126976, -0.006475137080997229, 0.07220625877380371, -0.10117048025131226, -0.08652256429195404, -0.0357944592833519, -0.044963184744119644, -0.051587678492069244, 0.09845782071352005, -0.020206809043884277, 0.05341384559869766, -0.0985269770026207, -0.025357641279697418, -0.14875300228595734, -0.056158408522605896, -0.12573209404945374, -0.020344529300928116, -0.05782783031463623, 0.06785617023706436, 0.06511665135622025, -0.11351548135280609, 0.07949822396039963, -0.0968715250492096, -0.03109622746706009, -0.012367615476250648, 0.24805673956871033, -0.09331139922142029, -0.0029704223852604628, 0.15025821328163147, 0.02389105036854744, 0.11149638146162033, 0.07977670431137085, 0.007262806408107281, -0.014053051359951496, -0.02435583807528019, 0.004627193324267864, -0.05768641084432602, 1.598314966835661e-32, -0.05350528284907341, 0.0761961042881012, -0.029898852109909058, 0.028358440846204758, -0.08837288618087769, 0.09320101886987686, 0.16332575678825378, 0.05349700525403023, -0.05107686296105385, -0.06683037430047989, -0.17846214771270752, 0.18250447511672974, -0.009534386917948723, 0.07700381428003311, -0.031029343605041504, -0.043528858572244644, -0.08210144191980362, 0.011112723499536514, 0.007306982763111591, -0.08489583432674408, -0.028380537405610085, 0.06962621957063675, -0.008756902068853378, 0.10399067401885986, 0.01575274020433426, 0.025046750903129578, -0.10255357623100281, -0.04286986216902733, 0.04544113576412201, 0.040845658630132675, -0.08917084336280823, 0.002789969090372324, 0.1482481211423874, -0.11030436307191849, -0.049718402326107025, -0.04252270609140396, -0.051281966269016266, -0.1233769953250885, 0.124850794672966, 0.05922386422753334, -0.023929955437779427, 0.14464247226715088, -0.009693627245724201, -0.13063354790210724, -0.022033091634511948, 0.005836088676005602, 0.019063107669353485, 0.03519347310066223, -0.06529766321182251, 0.01589500717818737, -0.04218718037009239, 0.08164297044277191, -0.012708690017461777, -0.06304724514484406, -0.025393083691596985, 0.006107071880251169, -0.11226020753383636, -0.1631573885679245, 0.036005422472953796, 0.11572103202342987, 0.052076391875743866, 0.09723544865846634, -0.03183852508664131, 0.0374293327331543, -0.2664812207221985, 0.18760335445404053, 0.01696017012000084, 0.044036172330379486, 0.006108775734901428, 0.16142892837524414, 0.016826599836349487, -0.1252996027469635, 0.12264268845319748, -0.017792195081710815, 0.17139703035354614, -0.10199598968029022, 0.056066833436489105, 0.09433755278587341, -0.035711321979761124, 0.07578055560588837, -0.09445025771856308, 0.09494854509830475, 0.03430338203907013, 0.14736628532409668, 0.0802793800830841, 0.05337321013212204, 0.1102825254201889, 0.11914120614528656, -0.08520954847335815, 0.012378077022731304, 0.0793805718421936, -0.05793589726090431, -0.13393332064151764, 0.12431755661964417, 0.011209355667233467, -1.4308317072248523e-32, 0.06554462015628815, 0.013003462925553322, -0.11830513924360275, -0.04389133304357529, -0.08353419601917267, 0.06501418352127075, 0.05052436888217926, 0.11976190656423569, -0.0027685724198818207, -0.033144693821668625, 0.09544703364372253, 0.06895602494478226, -0.05801130086183548, 0.020552486181259155, -0.06545524299144745, -0.05165726691484451, -0.014834048226475716, -0.17097410559654236, 0.0053395796567201614, 0.07099109888076782, 0.02996448241174221, 0.08319178968667984, -0.030259395018219948, 0.028172768652439117, -0.0023846763651818037, 0.05094796046614647, 0.053482040762901306, -0.0023804111406207085, 0.10951422154903412, 0.007564287632703781, -0.09613056480884552, -0.0685463473200798, -0.2411634624004364, -0.0288609080016613, -0.012248960323631763, -0.08898359537124634, 0.126872718334198, -0.12429098784923553, -0.10062523931264877, -0.12898027896881104, 0.09485316276550293, -0.06023230031132698, -0.05676484480500221, 0.00455852784216404, 0.07075110077857971, -0.018649380654096603, 0.027089731767773628, 2.3631379008293152e-05, 0.19024845957756042, 0.0781354010105133, 0.0933087170124054, -0.0013419575989246368, 0.008709367364645004, 0.05693718418478966, -0.20253616571426392, -0.0146155571565032, 0.030973557382822037, 0.008046998642385006, -0.11886008828878403, 0.03759046271443367, 0.007558094337582588, 0.05852123349905014, 0.020805487409234047, -0.06887155771255493, 0.058316104114055634, 0.11979957669973373, 0.04474770277738571, -0.04322656989097595, -0.036501385271549225, -0.17578580975532532, 0.02586899884045124, -0.12816566228866577, 0.09519977867603302, -0.1746118664741516, -0.03052443452179432, 0.15394248068332672, -0.011849414557218552, -0.21882057189941406, -0.010391373187303543, -0.012142904102802277, -0.006459468975663185, -0.017857789993286133, 0.04523174837231636, 0.02824900485575199, 0.02876415103673935, 0.053163930773735046, -0.0510362908244133, -0.02591000311076641, -0.091989666223526, 0.09447012841701508, -0.10231606662273407, -0.07287205755710602, -0.055671386420726776, 0.11699553579092026, 0.09986419975757599, -1.0052498566892609e-07, 0.1542205512523651, 0.09896621108055115, 0.006261841394007206, -0.026522096246480942, 0.035216160118579865, -0.07135909050703049, -0.07568582892417908, 0.07118149101734161, 0.03943941742181778, 0.1182088628411293, 0.07956035435199738, 0.16300952434539795, -0.17659327387809753, 0.04222675412893295, -0.1334468424320221, 0.07482375204563141, -0.13621069490909576, -0.00046170270070433617, -0.03680243343114853, -0.08868978917598724, -0.10558424890041351, 0.06595472246408463, -0.008115474134683609, -0.05551473796367645, 0.0012174793519079685, -0.08814117312431335, -0.030128560960292816, 0.018519431352615356, 0.012879226356744766, -0.049587566405534744, 0.06894032657146454, -0.10634352266788483, 0.030863843858242035, 0.01576818898320198, -0.05059606954455376, -0.21036425232887268, -0.07558909058570862, 0.016338303685188293, 0.05487090349197388, 0.07647942006587982, -0.009509417228400707, -0.037599317729473114, -0.05348808318376541, 0.03834611549973488, -0.015046435408294201, -0.09636448323726654, -0.24629029631614685, -0.10642549395561218, 0.07696792483329773, -0.03808891773223877, 0.03702481836080551, -0.04549211636185646, 0.0234996285289526, -0.07492442429065704, -0.0022760950960218906, 0.04908806085586548, 0.03098469413816929, -0.12115993350744247, -0.11105647683143616, 0.028517115861177444, 0.045610204339027405, -0.3023727834224701, 0.14200769364833832, 0.1354442536830902], "changes": {"1wk": -6.969917837774753}}, {"text": "High Growth Tech Stocks In The United States To Watch editorial-team@simplywallst.com (Simply Wall St) Thu, Jan 9, 2025, 9:04 PM 4 min read In This Article: ARQT -4.15% EVH -2.30% EXLS +1.37% The United States market has remained flat over the past week but has seen a significant rise of 23% in the last year, with earnings expected to grow by 15% annually in the coming years. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on these favorable market conditions. Top 10 High Growth Tech Companies In The United States Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 24.13% 24.28% \u2605\u2605\u2605\u2605\u2605\u2605 Ardelyx 22.86% 54.70% \u2605\u2605\u2605\u2605\u2605\u2605 AVITA Medical 33.38% 51.81% \u2605\u2605\u2605\u2605\u2605\u2605 Alkami Technology 21.99% 102.65% \u2605\u2605\u2605\u2605\u2605\u2605 Clene 61.16% 59.11% \u2605\u2605\u2605\u2605\u2605\u2605 Alnylam Pharmaceuticals 21.23% 56.37% \u2605\u2605\u2605\u2605\u2605\u2605 TG Therapeutics 29.99% 44.07% \u2605\u2605\u2605\u2605\u2605\u2605 Travere Therapeutics 28.68% 62.50% \u2605\u2605\u2605\u2605\u2605\u2605 Seagen 22.57% 71.80% \u2605\u2605\u2605\u2605\u2605\u2605 ImmunoGen 26.00% 45.85% \u2605\u2605\u2605\u2605\u2605\u2605 Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Arcutis Biotherapeutics Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2605\u2606 Overview: Arcutis Biotherapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for dermatological diseases, with a market cap of approximately $1.84 billion. Operations: Arcutis Biotherapeutics focuses on the development and commercialization of dermatological treatments, generating revenue primarily from its pharmaceuticals segment, which amounts to $138.71 million. Arcutis Biotherapeutics, a firm in the biotech sector, is navigating through an unprofitable phase with significant R&D investments aimed at groundbreaking dermatological treatments. Despite a current lack of profitability, Arcutis has demonstrated robust revenue growth at 29.8% annually and forecasts earnings to surge by approximately 59.6% per year. The company's recent submission of a supplemental New Drug Application for ZORYVE cream highlights its commitment to expanding treatment options for inflammatory skin conditions, potentially enhancing its market position upon successful approval. This strategic focus on specialized, high-demand medical solutions could set Arcutis on a path to future profitability and industry prominence despite present challenges like shareholder dilution and substantial insider selling over the past three months. Take a closer look at Arcutis Biotherapeutics' potential here in our health report. Understand Arcutis Biotherapeutics' track record by examining our Past report. NasdaqGS:ARQT Revenue and Expenses Breakdown as at Jan 2025 ExlService Holdings Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2606\u2606 Overview: ExlService Holdings, Inc. is a company that provides data analytics and digital operations solutions both in the United States and internationally, with a market capitalization of $7.10 billion. Story Continues Operations: ExlService Holdings generates revenue primarily through its Analytics, Insurance, Healthcare, and Emerging Business segments, with Analytics contributing $770.51 million. The company's diverse service offerings cater to various industries across global markets. ExlService Holdings, a contender in the professional services sector, is demonstrating notable financial agility with an 11.6% annual revenue growth and a more robust earnings increase of 15.3% per year. Recent strategic moves include a substantial share repurchase program, where $190 million was spent to buy back 3.28% of its shares, underscoring confidence in its operational stability and future prospects. Moreover, the launch of the EXL Enterprise AI Platform, developed on NVIDIA\u2019s framework, marks a significant step towards integrating advanced GenAI solutions into diverse client workflows\u2014potentially revolutionizing how businesses leverage technology for efficiency and growth. Click to explore a detailed breakdown of our findings in ExlService Holdings' health report. Evaluate ExlService Holdings' historical performance by accessing our past performance report. NasdaqGS:EXLS Revenue and Expenses Breakdown as at Jan 2025 Evolent Health Simply Wall St Growth Rating: \u2605\u2605\u2605\u2605\u2606\u2606 Overview: Evolent Health, Inc., via its subsidiary Evolent Health LLC, provides specialty care management services in oncology, cardiology, and musculoskeletal markets across the United States with a market capitalization of approximately $1.38 billion. Operations: Evolent Health LLC generates revenue primarily from its Pharmacy Services segment, which amounts to $2.46 billion. The company focuses on specialty care management in specific medical fields within the U.S. Evolent Health, amidst a volatile market, shows promise with a 12.4% annual revenue growth and an expected earnings surge of 63.5% per year. The recent expansion of its strategic partnership with Humana to streamline oncology services highlights its innovative approach in healthcare technology, enhancing patient care efficiency and approval processes. With R&D investments aligning with industry advancements and Dr. Von Nguyen's appointment as CMO poised to infuse fresh expertise into their operations starting January 2025, Evolent is strategically positioning itself to capitalize on tech-driven healthcare solutions. Navigate through the intricacies of Evolent Health with our comprehensive health report here. Gain insights into Evolent Health's historical performance by reviewing our past performance report. NYSE:EVH Revenue and Expenses Breakdown as at Jan 2025 Make It Happen Investigate our full lineup of 233 US High Growth Tech and AI Stocks right here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Looking For Alternative Opportunities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management . Find companies with promising cash flow potential yet trading below their fair value . This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ARQT NasdaqGS:EXLS and NYSE:EVH . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-09T18:04:54+00:00", "sentiment": {"score": 0.19211183115839958, "confidence": 0.20215043425559998, "probabilities": {"positive": 0.20215043425559998, "negative": 0.010038603097200394, "neutral": 0.7878109812736511}}, "embedding": [0.0288471058011055, -0.1765546053647995, -0.061269041150808334, -0.04765788093209267, 0.018604174256324768, -0.04962602257728577, -0.005721156485378742, 0.17899024486541748, 0.04831470176577568, 0.09303154051303864, -0.06494800001382828, 0.01754085160791874, 0.00796126201748848, 0.04993006959557533, -0.15163464844226837, -0.0219745934009552, 0.036961883306503296, -0.075981505215168, 0.007579274475574493, 0.008017923682928085, 0.0189015232026577, 0.005060702562332153, 0.00042361579835414886, 0.022443177178502083, 0.013011276721954346, -0.05584653839468956, -0.1113811582326889, -0.0689353346824646, -0.2898891568183899, -0.12489301711320877, -0.06840267777442932, 0.0704675018787384, 0.09695407748222351, -0.1091795414686203, -0.01374079380184412, -0.06833992898464203, -0.022026725113391876, 0.09146463125944138, 0.026983173564076424, 0.03657803311944008, -0.0971396267414093, -0.0066101569682359695, -0.10137492418289185, 0.07146008312702179, 0.05099277198314667, -0.21003907918930054, -0.05599808692932129, -0.011910253204405308, 0.029339369386434555, 0.1437634378671646, -0.13211581110954285, -0.05960322916507721, -0.024790365248918533, 0.07979395985603333, -0.06497928500175476, -0.02314479649066925, -0.13094750046730042, -0.00932462140917778, 0.0008082129061222076, -0.016959840431809425, 0.011999246664345264, -0.09816542267799377, 0.046231843531131744, -0.04689263552427292, 0.05054039508104324, -0.03219524770975113, 0.025516539812088013, 0.03284715488553047, -0.052213914692401886, -0.06537442654371262, 0.09916974604129791, -0.08550077676773071, -0.08862746506929398, 0.18412049114704132, -0.05072898417711258, 0.1478552520275116, 0.11862406879663467, 0.13301147520542145, 0.17747698724269867, -0.07174735516309738, 0.0714864432811737, 0.03221646696329117, -0.017477309331297874, 0.06317832320928574, -0.046537529677152634, 0.07381653785705566, 0.07093209773302078, 0.046109069138765335, 0.12513716518878937, -0.009839671663939953, 0.09531991183757782, 0.011490548960864544, -0.07228370010852814, 0.0030486392788589, -0.007980549708008766, 0.0019327476620674133, -0.12987913191318512, -0.01161658763885498, 0.004759624600410461, -0.04262227192521095, 0.04088238626718521, -0.1405818909406662, -0.050223276019096375, -0.01516057550907135, -0.08777600526809692, -0.13450628519058228, 0.05498075485229492, -0.009336613118648529, 0.11541366577148438, 0.07075565308332443, -0.019101832062005997, 0.031557925045490265, -0.149804025888443, -0.005821289494633675, -0.0801035612821579, 0.13427600264549255, 0.008398331701755524, -0.049592599272727966, 0.18115855753421783, -0.009682219475507736, 0.08149340748786926, 0.10503042489290237, -0.09307901561260223, -0.054713740944862366, -0.05701601505279541, 0.008840732276439667, -0.05334404110908508, 1.299487845935724e-32, -0.10054413974285126, 0.12706004083156586, -0.05944341421127319, 0.06859004497528076, -0.0564192458987236, -0.02234133705496788, 0.068453848361969, -0.017543485388159752, -0.1140274927020073, -0.09519754350185394, -0.3272211253643036, 0.16776521503925323, -0.044833578169345856, 0.1608751118183136, 0.03414495661854744, -0.11143418401479721, 0.059002432972192764, 0.07098788022994995, -0.01119307056069374, -0.09912291169166565, -0.04161439836025238, 0.1976163536310196, -0.08091821521520615, 0.02422350086271763, -0.06937826424837112, 0.007283197715878487, -0.14727848768234253, -0.04936140030622482, 0.022483818233013153, 0.05087417736649513, -0.0405297577381134, 0.05214732885360718, 0.06801579892635345, -0.07707815617322922, -0.01538754254579544, -0.0828162431716919, -0.0632534995675087, -0.11365041881799698, 0.18150107562541962, 0.030834367498755455, -0.060106560587882996, 0.12751874327659607, -0.1454714834690094, 0.007467699237167835, 0.05585852637887001, 0.023611491546034813, -0.12015104293823242, 0.04315078258514404, -0.01956198737025261, -0.06697151809930801, -0.07546920329332352, 0.08378641307353973, 0.04649319127202034, -0.026402609422802925, 0.013948246836662292, 0.12205272912979126, -0.1544293463230133, -0.13276778161525726, 0.129025399684906, 0.14566272497177124, -0.016401784494519234, 0.08848126232624054, 0.04439450800418854, 0.044818416237831116, -0.12867030501365662, 0.11624205112457275, 0.09440082311630249, 0.07275722175836563, -0.0061697689816355705, 0.19914959371089935, -0.018190067261457443, -0.038687676191329956, 0.1910930573940277, 0.02123241499066353, 0.09617617726325989, -0.0030595073476433754, -0.05901621654629707, 0.12269563227891922, -0.09734217077493668, 0.02109171263873577, -0.1280568540096283, 0.06046679615974426, -0.12867096066474915, 0.036238133907318115, 0.06738165020942688, 0.052095286548137665, -0.021175161004066467, 0.10834714770317078, -0.06639168411493301, -0.013963279314339161, 0.04742924124002457, -0.0702815055847168, -0.10398294031620026, 0.1270909309387207, -0.0442783385515213, -1.5751988704267408e-32, -0.007787549402564764, -0.08761529624462128, -0.011734538711607456, -0.10374607145786285, -0.048811063170433044, 0.09222808480262756, -0.02365383878350258, -0.0561508908867836, 0.04081331938505173, 0.017846472561359406, 0.009177562780678272, 0.13742251694202423, -0.09011490643024445, -0.03767837584018707, -0.039829812943935394, 0.001704419031739235, -0.015580677427351475, -0.10520806163549423, 0.007045915350317955, -0.07489175349473953, -0.010723882354795933, 0.050771381705999374, -0.17282018065452576, 0.09126503765583038, 0.09441976249217987, 0.02385256066918373, -0.06542421132326126, 0.033812783658504486, 0.1465592384338379, 0.015496760606765747, -0.09667778015136719, 0.010474884882569313, -0.15239594876766205, 0.10286203026771545, -0.018512379378080368, 0.08762707561254501, 0.02724768966436386, -0.13038811087608337, -0.043863870203495026, -0.10917412489652634, 0.07075092941522598, -0.08574491739273071, -0.02006390132009983, 0.06822659075260162, 0.1223621666431427, 0.023379655554890633, 0.01163837406784296, 0.04821406304836273, 0.08889388293027878, 0.010705186054110527, 0.1129920482635498, 0.05272538959980011, 0.02939959056675434, -0.0002184901386499405, -0.12425428628921509, -0.011265184730291367, -0.0551353394985199, 0.0680558830499649, -0.16670992970466614, -0.045900098979473114, 0.07106008380651474, 0.03404730185866356, -0.018727565184235573, 0.02863069251179695, -0.08281940966844559, 0.08731625229120255, 0.11409647762775421, -0.036353275179862976, -0.11185485124588013, -0.14032845199108124, 0.05963961407542229, -0.024395104497671127, 0.06284256279468536, -0.15606437623500824, -0.08976629376411438, 0.12375329434871674, 0.04711564630270004, -0.09905540943145752, -0.11657855659723282, 0.08913503587245941, 0.0327569879591465, 0.018870286643505096, 0.05401850491762161, 0.06063363701105118, -0.05653543397784233, 0.051152877509593964, -0.07808034121990204, -0.006000638008117676, -0.08922374248504639, 0.05987377092242241, -0.09027305990457535, -0.1685064285993576, -0.10402625054121017, -0.018756229430437088, 0.01149218063801527, -1.0174447595545644e-07, 0.18131090700626373, 0.003558443859219551, 0.004904665984213352, -0.05339168384671211, -0.003924119286239147, -0.04340938478708267, -0.07499981671571732, 0.19673027098178864, 0.06724750995635986, 0.14828287065029144, 0.028962865471839905, 0.11878973245620728, -0.12662164866924286, 0.03623736649751663, -0.08087369799613953, 0.04411757364869118, -0.05747532099485397, 0.09472598880529404, -0.008263971656560898, -0.09080423414707184, -0.04329308122396469, 0.10396067798137665, 0.05328398570418358, -0.07485485076904297, 0.018889935687184334, -0.0584634430706501, -0.09628549963235855, -0.08833830803632736, -0.050952550023794174, 0.040556650608778, 0.12225933372974396, -0.1089303195476532, 0.052071839570999146, 0.03367359936237335, 0.09562280029058456, -0.0748157799243927, -0.027490347623825073, 0.015075335279107094, 0.07356506586074829, 0.028196342289447784, 0.0009997319430112839, -0.019409535452723503, 0.02435028739273548, -0.0059042032808065414, -0.02780328318476677, -0.08386842161417007, -0.1872691810131073, -0.014926791191101074, 0.15232327580451965, -0.12324114143848419, 0.03796481713652611, -0.04646023362874985, -0.039932020008563995, -0.08962170034646988, -0.07867871224880219, 0.10427802056074142, -0.04510367661714554, -0.1601378619670868, -0.0946836844086647, 0.019039029255509377, 0.11723147332668304, -0.23380759358406067, 0.2250005006790161, 0.1940464973449707], "changes": {"1wk": -0.4344708022707254}}, {"text": "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Arcutis Biotherapeutics, Inc. Tue, Jan 7, 2025, 12:00 AM 3 min read In This Article: ARQT -4.15% Arcutis Biotherapeutics, Inc. WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 75,500 restricted stock units of Arcutis\u2019 common stock to eight newly hired employees. These awards were approved by the Compensation Committee of Arcutis\u2019 Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of January 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates. Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis\u2019 dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn , Facebook , Instagram , and X . Forward-Looking Statements Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company\u2019s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the \u201cRisk Factors\u201d section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Story Continues Contacts: Media Amanda Sheldon, Head of Corporate Communications media@arcutis.com Investors Latha Vairavan, Vice President, Finance and Corporate Controller ir@arcutis.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "ARQT", "date": "2025-01-06T21:00:00+00:00", "sentiment": {"score": 0.13271788321435452, "confidence": 0.14199887216091156, "probabilities": {"positive": 0.14199887216091156, "negative": 0.009280988946557045, "neutral": 0.848720133304596}}, "embedding": [-0.06678993999958038, -0.04728151112794876, 0.011533830314874649, -0.02535015158355236, -0.02076876536011696, 0.03686479106545448, -0.003216903191059828, 0.12583476305007935, -0.06535026431083679, 0.11059603095054626, -0.05358140170574188, -0.11623150110244751, 0.12259132415056229, 0.1376006007194519, -0.1060221940279007, 0.005826103501021862, 0.08630527555942535, 0.04212618246674538, -0.1200687363743782, -0.00906639639288187, 0.011852452531456947, 0.05207390338182449, -0.025654830038547516, 0.010875895619392395, -0.06796137243509293, -0.15512654185295105, -0.09625343978404999, -0.10457737743854523, -0.20947787165641785, -0.08818283677101135, -0.04113653302192688, 0.020488103851675987, 0.07403276860713959, -0.08020198345184326, -0.01622760482132435, -0.04084358736872673, -0.0749000608921051, 0.06812089681625366, -0.0002704570069909096, 0.12511293590068817, -0.12305876612663269, -0.09350956976413727, -0.0820118635892868, 0.08062611520290375, 0.0822431892156601, -0.08197639882564545, -0.013820933178067207, -0.032100334763526917, -0.019018419086933136, 0.23385977745056152, 0.007639653980731964, 0.004754895344376564, 0.0034966319799423218, 0.13327881693840027, -0.11726628243923187, -0.036538489162921906, -0.07754455506801605, -0.08751703798770905, -0.04588364064693451, 0.04099747911095619, -0.007780828513205051, -0.19767411053180695, 0.010111228562891483, -0.002199473325163126, 0.03540585935115814, -0.09926185011863708, 0.02168014831840992, -0.01300286315381527, 0.03570272773504257, -0.08687472343444824, 0.06335563957691193, -0.08422565460205078, -0.09612837433815002, 0.256808340549469, 0.11252444982528687, 0.3086669147014618, 0.07159042358398438, 0.21231836080551147, 0.15550293028354645, -0.22112378478050232, 0.06973680853843689, 0.1877530813217163, 0.12179601192474365, 0.0075262258760631084, 0.05789241939783096, 0.025212949141860008, -0.004805079661309719, 0.07988539338111877, 0.05102615803480148, 0.002985058818012476, 0.22605735063552856, 0.035822026431560516, 0.07039861381053925, -0.030472252517938614, 0.027988974004983902, -0.09048847109079361, -0.05167175084352493, 0.059203531593084335, 0.000633997842669487, 0.0004795873537659645, -0.09232686460018158, -0.17381072044372559, -0.2047615945339203, 0.011385098099708557, -0.046177107840776443, -0.1426236480474472, -0.0045765722170472145, -0.13687141239643097, 0.07416427135467529, 0.04776611179113388, 0.022608408704400063, 0.037187568843364716, -0.037802405655384064, -0.07779070734977722, -0.03868122398853302, 0.25344303250312805, -0.0014175660908222198, -0.04276348650455475, 0.17846420407295227, -0.0147128626704216, 0.09055115282535553, 0.026713650673627853, 0.024099886417388916, -0.13988198339939117, -0.03541116788983345, -0.030911769717931747, -0.040278635919094086, 1.1054842582760137e-32, -0.05321770906448364, 0.1112014427781105, -0.07253926992416382, 0.0430818572640419, -0.026599403470754623, -0.06025070697069168, 0.09663406759500504, 0.0014448324218392372, -0.06864470988512039, -0.005223019048571587, -0.23563233017921448, 0.27990323305130005, 0.022178655490279198, 0.16303610801696777, -0.06885064393281937, 0.020404785871505737, 0.07543185353279114, 0.08811427652835846, -0.05403366684913635, -0.04845617711544037, 0.030235927551984787, 0.12590070068836212, -0.1014866828918457, 0.07709091156721115, 0.011972221545875072, 0.08638938516378403, -0.14053161442279816, -0.01727474480867386, 0.03604945167899132, 0.08588294684886932, -0.00915399007499218, 0.05651713162660599, 0.1295684576034546, -0.0965241938829422, -0.046042218804359436, -0.0450306162238121, -0.05631094425916672, -0.12802498042583466, 0.13480304181575775, -0.031665705144405365, -0.05168771743774414, 0.05416324734687805, 0.01754346676170826, -0.10918378829956055, 0.018700651824474335, -0.06687047332525253, -0.0921565443277359, 0.05786329507827759, -0.1460021734237671, 0.13525846600532532, 0.0033919792622327805, 0.04276018217206001, 0.08562316745519638, -0.07169551402330399, 0.008954960852861404, 0.020723747089505196, -0.17063301801681519, -0.06659851968288422, 0.15345466136932373, 0.10898919403553009, 0.08225056529045105, 0.12799154222011566, -0.05786098539829254, 0.09171145409345627, -0.19892725348472595, 0.037104301154613495, 0.005429090932011604, -0.03352237865328789, 0.11643016338348389, 0.11593827605247498, -0.007797301281243563, 0.08256392180919647, 0.02729189395904541, -0.022873273119330406, 0.10782530903816223, -0.14625251293182373, 0.07227696478366852, 0.18500451743602753, -0.10050490498542786, -0.04075763002038002, -0.059962887316942215, 0.10782922804355621, -0.017469584941864014, 0.08802789449691772, 0.13708746433258057, 0.057410962879657745, 0.05381949990987778, 0.1479358971118927, -0.13433709740638733, -0.06270261108875275, 0.17737862467765808, 0.0021032430231571198, -0.050318725407123566, 0.18909090757369995, 0.0536448135972023, -1.0505279871967517e-32, 0.06793321669101715, -0.028537750244140625, -0.18926465511322021, -0.135940819978714, 0.008595429360866547, 0.10050499439239502, 0.047784049063920975, -0.08472364395856857, -0.014951750636100769, 0.0006461106240749359, 0.12487655878067017, 0.01856416091322899, -0.04674098640680313, -0.08615589141845703, -0.08761923015117645, -0.0425729900598526, -0.05324744060635567, -0.1212848424911499, -0.11821476370096207, 0.09587375819683075, 0.008125467225909233, 0.09031230211257935, -0.07091633975505829, 0.04564441740512848, 0.030652716755867004, 0.004419457633048296, 0.016043249517679214, 0.0007584467530250549, 0.12671636044979095, 0.016455702483654022, -0.18398642539978027, -0.04580414667725563, -0.24907536804676056, -0.030430076643824577, -0.039612334221601486, -0.12090154737234116, 0.06798923760652542, -0.1586320400238037, -0.06314478814601898, 0.0026090655010193586, 0.11848278343677521, -0.10506295412778854, -0.054904576390981674, 0.053444601595401764, 0.045174792408943176, 0.009368060156702995, 0.031007234007120132, -0.03156201168894768, 0.10258425027132034, -0.0311955064535141, 0.09008201211690903, -0.10663680732250214, 0.1773289442062378, 0.041596122086048126, -0.07353105396032333, -0.04890121519565582, 0.04800086095929146, 0.006086957640945911, 0.004346948582679033, 0.053055811673402786, 0.06156573072075844, 0.04343751445412636, -0.015326622873544693, -0.0163937509059906, 0.061560072004795074, 0.04426801949739456, 0.015530874952673912, -0.05934847146272659, -0.07453499734401703, -0.060982540249824524, -0.04908650368452072, -0.0808032676577568, 0.04468045011162758, -0.2164347618818283, -0.04156216233968735, 0.019915089011192322, 0.01870046555995941, -0.18349601328372955, -0.1823793649673462, 0.08110897243022919, -0.05031989514827728, -0.09691076725721359, 0.07092652469873428, 0.09518338739871979, 0.08877268433570862, 0.0033151290845125914, 0.006781996227800846, 0.012045065872371197, -0.06049540638923645, 0.10981085896492004, -0.069691963493824, -0.11157221347093582, -0.06912195682525635, 0.12214457988739014, -0.012688335962593555, -1.0084363566420507e-07, 0.17194730043411255, 0.08380433917045593, -0.07164287567138672, -0.0783667266368866, -0.022573241963982582, -0.038262080401182175, -0.17918303608894348, 0.10508110374212265, 0.004501553252339363, 0.10701608657836914, 0.13652130961418152, 0.20070573687553406, -0.09492026269435883, 0.04722268134355545, -0.04122891277074814, 0.05256211385130882, -0.02454187721014023, 0.023124882951378822, -0.06867489963769913, -0.1383843719959259, -0.14089135825634003, 0.031399067491292953, -0.026776764541864395, -0.06663239002227783, -0.011803033761680126, -0.0095969894900918, 0.04216068983078003, 0.03783249855041504, 0.05365433916449547, -0.0857820063829422, 0.03425932675600052, -0.12481360137462616, -0.015327639877796173, -0.014375755563378334, -0.06458300352096558, -0.08427014946937561, -0.010156910866498947, -0.05174674093723297, 0.10251646488904953, 0.09357266128063202, -0.02120913192629814, 0.07024392485618591, -0.01593516767024994, 0.023985113948583603, -0.0213642381131649, -0.0017340760678052902, -0.19353793561458588, -0.08999238908290863, -0.004663141909986734, -0.09141063690185547, -0.012850022874772549, -0.09219735860824585, 0.009581360965967178, -0.0008451994508504868, -0.018854616209864616, 0.052100345492362976, 0.048982828855514526, -0.21848474442958832, 0.017486173659563065, 0.03454410657286644, 0.029283341020345688, -0.10777100175619125, 0.17991405725479126, 0.11457548290491104], "changes": {"1wk": -7.341943717915196}}]